Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14804129 | 0.85 | EPHX1 (0.54) | DPP4EPHX1GAAEPHX2ALDH1A1 | |
| SCHEMBL5608146 | 0.79 | POLB (0.41) | DPP8DPP9ALDH1A1POLBNAAA | |
| SCHEMBL3363251 | 0.75 | DPP8 (0.48) | DPP4EPHX2DPP8DPP9ALDH1A1 | |
| SCHEMBL5179241 | 0.75 | POLB (0.50) | EPHX2DPP8DPP9POLBNAAA | |
| SCHEMBL5608432 | 0.74 | GRIN2D (0.43) | DPP8DPP9ALDH1A1POLBNPC1 | |
| SCHEMBL3366010 | 0.73 | POLB (0.45) | DPP4DPP8DPP9POLBNAAA | |
| SCHEMBL12205968 | 0.73 | POLB (0.41) | DPP8DPP9ALDH1A1KMT2APOLB | |
| SCHEMBL27356480 | 0.72 | DPP8 (0.41) | DPP4DPP8DPP9POLBNAAA | |
| Hydrochloric Acid SCHEMBL27804946 | 0.72 | POLB (0.44) | DPP4DPP8DPP9POLBNAAA | |
| SCHEMBL31732779 | 0.71 | DPP8 (0.53) | DPP4DPP8DPP9POLBNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569250-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-10-29 | — | — | US | disclosed |
| EP-2247602-B1 | ADAMANTYL O-GLUCURONIDE DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | NOVARTIS AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| US-20120295860-A1 | ORGANIC COMPOUNDS | HASSIEPEN ULRICH (DE) | 2012-11-22 | — | — | US | disclosed |
| US-8252751-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-08-28 | — | — | US | disclosed |
| US-20100256080-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-07 | — | — | US | disclosed |
| EP-1137635-B1 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 2005-10-19 | — | — | EP | disclosed |
| US-6166063-A | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV | NOVARTIS AG (CH) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256080-A1 | ORGANIC COMPOUNDS | DPP4, DPP7, DPP3 | DPP4 1/4885EPHX1 2943/4885GAA 399/4885 |
| US-20120295860-A1 | ORGANIC COMPOUNDS | DPP4, DPP7, DPP3 | DPP4 1/4885EPHX1 2936/4885GAA 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.